Vertex to end sales of hepatitis C drug Incivek

[riky]

Vertex to end sales of hepatitis C drug Incivek

(Reuters) - Vertex Pharmaceuticals Inc is stopping U.S. sales and distribution of its Incivek hepatitis C treatment, whose use has been largely supplanted by the new Sovaldi drug from Gilead Sciences Inc. On Monday, Vertex sent a letter to doctors who treat patients with liver wasting disease to inform them that it would not be available after Oct. 14, a company spokesman confirmed on Wednesday. Vertex said in May during a conference call with analysts that it would withdraw from the hepatitis C market but had not said when it would stop making the drug. Incivek was approved in 2011 and quickly rose to annual sales of more than $1 billion. Vertex shares were up 3.7 percent to $88.58 on Wednesday.

Source: You are not allowed to view links. Register or Login